FBR Capital Cuts Price Target on Athenahealth (ATHN) Following 2Q Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Deutsche Bank Downgrades athenahealth (ATHN) to Hold
July 22, 2016 6:58 AM EDTDeutsche Bank downgraded athenahealth (NASDAQ: ATHN) from Buy to Hold with a price target of $147.00 (from $165.00). Analyst George Hill pointed out disturbing underlying performance metrics.
"Athena reported concerning Q2 results after market close, where the revenue and earnings miss was among the... More
After-Hours Stock Movers 07/21 (PBYI) (EYES) (PFPT) Higher; (SKX) (ATHN) (P) Lower (more...)
July 21, 2016 5:59 PM EDTToday's After-Hours Movers
Puma Biotechnology, Inc. (NYSE: PBYI) 18.8% HIGHER; submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate PB272 (neratinib) for the extended adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab (Herceptin®)-based therapy. Also, announced updated results from the Phase III clinical trial of Pumas investigational drug PB272 (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer (ExteNET trial). The ExteNET trial is a... More
UPDATE: Athenahealth (ATHN) Misses Q2 EPS by 8c, COO to Step Down at Year-End
July 21, 2016 4:06 PM EDT(Updated - July 25, 2016 10:31 AM EDT)
(Update corrects headline to say COO to step down, not CEO)
Athenahealth (NASDAQ: ATHN) reported Q2 EPS of $0.34, $0.08 worse than the analyst estimate of $0.42. Revenue for the quarter came in at $261.9 million versus the consensus estimate of $274.07... More
